Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.